Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Primary objective:
- End-point improvement from baseline in Male Sexual Health Questionnaire Ejaculation
domain (MSHQ-EjD)in men with lower urinary tract symptoms (LUTS)suggestive of benign
prostatic hyperplasia (BPH) treated for 6 months with XATRAL 10mg once daily OD.
Secondary objectives:
- MSHQ-EjD improvement by visit
- Improvement in International Prostate Symptom Score (IPSS) total score, voiding and
filling subscores, nocturia and bother score at end-point and by visit
- Onset of action of XATRAL 10mg OD
- Tolerability of XATRAL 10mg OD including occurrence of acute urinary retention.